BLC
EW icon

Brown, Lisle/Cummings’s Edwards Lifesciences EW Stock Holding History

Brown, Lisle/Cummings’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.21K Buy
65
+23
+55% +$1.9K ﹤0.01% 671
2025
Q4 		$3.58K Hold
42
– – ﹤0.01% 584
2025
Q3 		$3.27K Hold
42
– – ﹤0.01% 605
2025
Q2 		$3.29K Hold
42
– – ﹤0.01% 608
2025
Q1 		$3.04K Buy
42
+11
+35% +$787 ﹤0.01% 612
2024
Q4 		$2.29K Buy
+31
New +$2.17K ﹤0.01% 595

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Brown, Lisle/Cummings's EW Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its Edwards Lifesciences (EW) stake by 55% in Q1 2026, buying an estimated $1.9K and bringing the position to 65 shares worth $5.21K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Brown, Lisle/Cummings first reported a position in EW in Q4 2024 and has held it in 6 quarters since. 1,288 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Brown, Lisle/Cummings held 65 shares of Edwards Lifesciences worth $5.21K as of Q1 2026.
  • Brown, Lisle/Cummings bought 23 Edwards Lifesciences shares in Q1 2026, an estimated $1.9K.
  • Edwards Lifesciences made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #671 holding.
  • Brown, Lisle/Cummings first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 6 quarters since.
  • 1,288 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.